Physician profile
Kenneth Erdman
NPI 1639118797
$9,513.72
in general payments reported to CMS, 2019-2025
42 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,413 · 2020: $354 · 2021: $924 · 2022: $1,568 · 2023: $1,518 · 2024: $1,347 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,254.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,601.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,157.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $919.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $824.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $805.45 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $543.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $529.49 | 2021-2025 | |
| Abbott Laboratories | $341.09 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.60 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $214.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $204.78 | 2019-2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $193.24 | 2019-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $161.04 | 2019-2024 | |
| Amarin Pharma, INC. | $158.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $154.46 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $150.51 | 2019-2025 | Repatha, Otezla |
| Astellas Pharma US INC | $140.16 | 2021-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $129.47 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $121.54 | 2023-2025 | Dexcom G6 Transmitter |
| Cequr Corporation | $113.83 | 2023-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $112.96 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $94.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.23 | 2019-2024 | Glassia, Trintellix |
| Organon LLC | $69.80 | 2022-2024 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $58.19 | 2019-2025 | Rexulti |
| Allergan, INC. | $56.94 | 2019-2020 | |
| Axsome Therapeutics, INC. | $50.17 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $44.80 | 2024-2025 | Eliquis |
| Phathom Pharmaceuticals, INC. | $39.01 | 2025 | Voquezna |
| Celgene Corporation | $29.77 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.41 | 2022 | |
| Lundbeck LLC | $21.88 | 2025 | Rexulti |
| Ardelyx, INC. | $19.13 | 2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $17.63 | 2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $16.73 | 2025 | Opsynvi |
| Biogen, INC. | $16.62 | 2022 | |
| Watermark Medical, INC. | $13.37 | 2024 | |
| Eisai INC. | $13.32 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.66 | 2020 | |
| Sanofi Pasteur INC. | $11.93 | 2022 | |
| Genentech USA, INC. | $11.16 | 2019 | |
| Daiichi Sankyo INC. | $10.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Erdman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.